Press Releases

29.04.2022
DGAP-Media

Aladdin Healthcare Technologies SE announces Delay in the publication of 2021 Annual Financial Statements

BERLIN/LONDON April 29, 2022 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces that, due to delays in the audit of Aladdin Healthcare Technologies SE and additional time being required by the Company to finalise the 2021 annual results, the Company is not in a position to meet the deadline for the publication of its audited annual financial statements for the financial year ended 31 December 2021. The deadline falls due 30 April 2022.

The Company will be using its best endeavours to ensure that the audit of the annual financial statements for the financial year ended 31 December 2021 will be completed as soon as possible. The Company will publish an update regarding the time of publication as soon as it is foreseeable when the work on the financial statements can be completed.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de